The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance

Jorge J. Castillo, Natalie S. Callander, Douglas W. Sborov, Shaji Kumar

Research output: Contribution to journalReview articlepeer-review

Abstract

Despite the benign nature of monoclonal gammopathy of undetermined significance (MGUS), mounting data are associating MGUS with the development of organ dysfunction, specifically monoclonal gammopathy of renal significance (MGRS) and monoclonal gammopathy of neurological significance (MGNS), which could be associated with substantial morbidity. Emerging evidence suggests that patients with MGRS and MGNS could benefit from treatments used for myeloma, Waldenström macroglobulinemia, or chronic lymphocytic leukemia, depending on the underlying pathology. However, the treatment of MGRS and MGNS is not standardized, and potentially effective therapies might not be reimbursed because these conditions do not formally meet the criteria for malignant processes. The present review aims at establishing standards for the evaluation and management of MGRS and MGNS, which can facilitate the diagnosis of and provide therapeutic options for treating practitioners and patients affected by these conditions. The careful design and execution of clinical trials for patients with MGRS and MGNS are positively encouraged.

Original languageEnglish (US)
JournalAmerican journal of hematology
DOIs
StateAccepted/In press - 2021

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance'. Together they form a unique fingerprint.

Cite this